Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $27.0 million.

  • Keros Therapeutics' Non-Current Assets fell 13.77% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year decrease of 13.77%. This contributed to the annual value of $27.0 million for FY2024, which is 18.74% up from last year.
  • Per Keros Therapeutics' latest filing, its Non-Current Assets stood at $27.0 million for FY2024, which was up 18.74% from $22.7 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Non-Current Assets registered a high of $27.0 million during FY2024, and its lowest value of $1.7 million during FY2020.
  • Over the past 3 years, Keros Therapeutics' median Non-Current Assets value was $22.7 million (recorded in 2023), while the average stood at $23.6 million.
  • As far as peak fluctuations go, Keros Therapeutics' Non-Current Assets declined by 15.34% in 2020, and later soared by 451.40% in 2022.
  • Over the past 5 years, Keros Therapeutics' Non-Current Assets (Yearly) stood at $1.7 million in 2020, then skyrocketed by 121.96% to $3.8 million in 2021, then skyrocketed by 451.40% to $21.0 million in 2022, then increased by 8.18% to $22.7 million in 2023, then grew by 18.74% to $27.0 million in 2024.